Minimally invasive techniques cut mortality in early rectal cancer

Transanal endoluminal surgery (TES) shows significant advantages over endoscopic submucosal dissection (ESD) for T1 rectal cancer.

1-year mortality: 2.3% for TES vs. 10.1% for ESD; 10-year mortality: 11.6% vs. 27.1%.
Hospital readmissions at 1 month: 3.4% for TES vs. 19.6% for ESD.
Fewer complications with TES, including reduced procedural pain and thromboembolic events.

Choose TES for lower mortality and complications, tailoring decisions to patient-specific factors.

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in Intestine and Lower Gastrointestinal Tract.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

More in Intestine and Lower Gastrointestinal Tract

Ann Surg Oncol2 Nov 2026

Patients smoking at diagnosis were less likely to have a favorable response to treatment before rectal cancer surgery; former smokers were not.

JAMA Surg30 Oct 2026

For severe slow-transit constipation, removing less colon gave similar symptom relief at one year, with less early incontinence.

Surg Endosc29 Oct 2026

In low rectal cancer surgery, removing the specimen through the anus was linked to fewer wound complications and less pain in the first two days.